FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W152124639> ?p ?o ?g. }

• W152124639 endingPage "16509" @default.
• W152124639 startingPage "16509" @default.
• W152124639 abstract "16509 Background: ARQ 501 is a DNA damage checkpoint pathway activator whose effect is to induce selective cell death in cancer cells, independent of the tumor cell's p53 status. Current evidence implicates a rapid and sustained increase of the pro-apoptotic protein E2F-1 by ARQ 501 as the mechanism of action. Cancer cells are selectively affected due to their pre-existing DNA damage. In initial clinical trials, there was evidence of activity in some patients with head and neck cancer and pre-clinical investigations also supported this application. Therefore, a phase 2 trial is warranted in this patient population. Methods: A phase 2 study in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck who had received up to 3 prior systemic therapies was initiated to assess overall response rate, progression free survival at six months, and to further characterize safety. Cycles consist of four weekly administrations of ARQ 501 at a dose of 450 mg/m 2 . Dose escalation is allowed if a patient successfully completed a full cycle of therapy and had no related grade 2 adverse events. Results: 59 patients have been enrolled to date and 47 have received at least one infusion of ARQ 501. Data is available for 34 patients (27M / 7F, median age, 57 years). Of the 47 patients treated, 11 patients did not reach a post baseline assessment (2 deaths, 8 PD prior to week 8 and 1 withdrew consent). Although at the current date, most patients have not reached their first tumor evaluation, 5 have been assessed for response per RECIST at eight weeks and one patient is demonstrating stable disease. The drug has been well tolerated with the most common adverse event being anemia (11% ) with corresponding edema, fatigue (both 5%), dyspnea (4%), and hyperbilirubinemia (2%). Conclusions: ARQ 501 is well tolerated in patients with advanced, recurrent or persistent squamous cell carcinoma of the head and neck. Enrollment is ongoing and further results will be presented. No significant financial relationships to disclose." @default.
• W152124639 created "2016-06-24" @default.
• W152124639 creator A5005012398 @default.
• W152124639 creator A5013122305 @default.
• W152124639 creator A5017361204 @default.
• W152124639 creator A5027249230 @default.
• W152124639 creator A5037776974 @default.
• W152124639 creator A5063904421 @default.
• W152124639 creator A5064206524 @default.
• W152124639 creator A5064319129 @default.
• W152124639 creator A5075093602 @default.
• W152124639 date "2007-06-20" @default.
• W152124639 modified "2023-09-25" @default.
• W152124639 title "A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck" @default.
• W152124639 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.16509" @default.
• W152124639 hasPublicationYear "2007" @default.
• W152124639 type Work @default.
• W152124639 sameAs 152124639 @default.
• W152124639 citedByCount "17" @default.
• W152124639 countsByYear W1521246392013 @default.
• W152124639 countsByYear W1521246392014 @default.
• W152124639 countsByYear W1521246392015 @default.
• W152124639 countsByYear W1521246392016 @default.
• W152124639 countsByYear W1521246392018 @default.
• W152124639 countsByYear W1521246392019 @default.
• W152124639 countsByYear W1521246392021 @default.
• W152124639 countsByYear W1521246392023 @default.
• W152124639 crossrefType "journal-article" @default.
• W152124639 hasAuthorship W152124639A5005012398 @default.
• W152124639 hasAuthorship W152124639A5013122305 @default.
• W152124639 hasAuthorship W152124639A5017361204 @default.
• W152124639 hasAuthorship W152124639A5027249230 @default.
• W152124639 hasAuthorship W152124639A5037776974 @default.
• W152124639 hasAuthorship W152124639A5063904421 @default.
• W152124639 hasAuthorship W152124639A5064206524 @default.
• W152124639 hasAuthorship W152124639A5064319129 @default.
• W152124639 hasAuthorship W152124639A5075093602 @default.
• W152124639 hasConcept C121608353 @default.
• W152124639 hasConcept C126322002 @default.
• W152124639 hasConcept C141071460 @default.
• W152124639 hasConcept C143998085 @default.
• W152124639 hasConcept C197934379 @default.
• W152124639 hasConcept C2776530083 @default.
• W152124639 hasConcept C2908647359 @default.
• W152124639 hasConcept C31760486 @default.
• W152124639 hasConcept C535046627 @default.
• W152124639 hasConcept C71924100 @default.
• W152124639 hasConcept C99454951 @default.
• W152124639 hasConceptScore W152124639C121608353 @default.
• W152124639 hasConceptScore W152124639C126322002 @default.
• W152124639 hasConceptScore W152124639C141071460 @default.
• W152124639 hasConceptScore W152124639C143998085 @default.
• W152124639 hasConceptScore W152124639C197934379 @default.
• W152124639 hasConceptScore W152124639C2776530083 @default.
• W152124639 hasConceptScore W152124639C2908647359 @default.
• W152124639 hasConceptScore W152124639C31760486 @default.
• W152124639 hasConceptScore W152124639C535046627 @default.
• W152124639 hasConceptScore W152124639C71924100 @default.
• W152124639 hasConceptScore W152124639C99454951 @default.
• W152124639 hasIssue "18_suppl" @default.
• W152124639 hasLocation W1521246391 @default.
• W152124639 hasOpenAccess W152124639 @default.
• W152124639 hasPrimaryLocation W1521246391 @default.
• W152124639 hasRelatedWork W1586374228 @default.
• W152124639 hasRelatedWork W2003938723 @default.
• W152124639 hasRelatedWork W2047967234 @default.
• W152124639 hasRelatedWork W2118496982 @default.
• W152124639 hasRelatedWork W2364998975 @default.
• W152124639 hasRelatedWork W2369162477 @default.
• W152124639 hasRelatedWork W2423163941 @default.
• W152124639 hasRelatedWork W2439875401 @default.
• W152124639 hasRelatedWork W4238867864 @default.
• W152124639 hasRelatedWork W2525756941 @default.
• W152124639 hasVolume "25" @default.
• W152124639 isParatext "false" @default.
• W152124639 isRetracted "false" @default.
• W152124639 magId "152124639" @default.
• W152124639 workType "article" @default.